Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin

Fig. 2

Knocking down or out EEF1D gene expression increased the sensitivity of human ovarian cancer cells to DDP in vitro. A The viabilities of ovarian cancer cells with DDP treatment in SKOV3 cell line stably knocked down and out EEF1D gene. B The viabilities of ovarian cancer cells with DDP treatment in SKOV3/DDP cell line stably knocked down and out EEF1D gene. C The viabilities of ovarian cancer cells with DDP treatment in Human primary ovarian cancer cells transiently knocked down EEF1D gene in 5 ovarian cancer patients. Data in A, B and C are mean ± SD, the experiment was performed with sextuplicate in three independent sets, *P < 0.05, **P < 0.01 compared with SKOV3, SKOV3/DDP or POCC intervened by DDP at the same concentration, #P < 0.05, ##P < 0.01 compared with SKOV3/KD, SKOV3/DDP/KD or POCC/scrambled shRNA intervened by DDP at the same concentration. D Representative flow cytometry dot plot of human ovarian cancer cell lines stained with annexin-V-FITC and PI. E Histogram of apoptosis rates of human ovarian cancer cell lines. F Representative flow cytometry dot plot of human primary ovarian cancer cells stained with annexin-V-FITC and PI in 5 ovarian cancer patients. G Histogram of apoptosis rates of POCC. The data in E and G are shown as means ± SD (E:n = 6; G:n = 10), **P < 0.01 vs. control, KD or KO group, respectively; ##P < 0.01 vs. control+DDP group. POCC: primary ovarian cancer cell

Back to article page